Psychedelics May Be the Next Big Investment Venture

The Controlled Substances Act was passed in the United States in the 1970s. The president at the time, Richard Nixon, approved the act as part of his war on drugs campaign. Under the act, cannabis was classified as a schedule 1 drug and was classified together with heroin and cocaine as extremely illegal and dangerous substances that were not allowed to be utilized in any medical applications.

Currently, the legal cannabis market in the world is growing each year at an average of 40% and is valued at $17 billion. This is mainly attributed to the emerging research showing that marijuana holds many benefits that can be utilized in various fields. Apart from this research changing how the public views cannabis, it has also opened doors for the legalization of cannabis in different states in the U.S. and other countries across the globe.

A lot of academic research came to light on the medical benefits of cannabis in the 2000s. The entertainment scene also helped portray the drug as something that wasn’t so dangerous in movies such as “Harold and Kumar,” further erasing its demonized history. Today, cannabis is one of the largest consumer markets in the world.

Currently, psychedelics are also booming, with substances such as LSD and ketamine being studied for their medicinal benefits. Just as with marijuana, society has for the longest time demonized psychedelics as drugs that are to be avoided at all costs. It may, therefore, come as a shock to some people to know that things weren’t always like this.

In the 1950s, a team of psychiatrists in California, led by Humphry Osmond, experimented with psychedelics and discovered that the hallucinogenic drugs possessed powerful therapeutic potential. However, the 1960s arrived, with backlash that halted the group’s research and resulted in psychedelics being included in the schedule 1 drug list in the 1970s — the final nail in the coffin.

This was the case until a decade ago, when academic research in the psychedelic field reopened that chapter. Recent studies from Johns Hopkins have discovered that psilocybin, which is an active ingredient found in hallucinogenic mushrooms, can decrease alcohol dependence and help people stop smoking.

A different study from the same prestigious institution that was published this year reported that psilocybin can help alleviate levels of depression and anxiety in patients who have terminal illness diagnoses; the report noted that the component worked four times better than any antidepressant currently on the market.

As we can see, psychedelic medicines have a lot of therapeutic potential. With laws that govern psychedelic substances also changing, we should expect a boom in the psychedelics market. If you missed out on investing in the marijuana market, watch this market closely. Pay attention to several stocks and monitor their growth to see if you can find what meets your investment criteria.

Currently, a number of firms have emerged in the functional mushrooms space. For instance, Rritual Superfoods Inc. has a line of products that contain adaptogens, functional mushrooms and a host of other superfoods. These products are aimed at helping users fight stress, boost their immunity and improve brain function.

NOTE TO INVESTORS: The latest news and updates relating to Rritual Superfoods Inc. are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050